rheumatologyadvisor.com
Early Anti-TNFα Therapy Cuts Perianal Fistula Complications in Pediatric Crohn Disease
Perianal fistulas are serious, hard-to-treat complications in pediatric Crohn disease. The study suggests starting anti-TNFα therapy early — especially for kids with perianal lesions — may lower the chance of developing these complications.
Pediatric patients with Crohn disease, their parents and caregivers, pediatric gastroenterologists, and clinicians who manage IBD.
What To Know
Early anti-TNFα given to pediatric Crohn's patients was associated with markedly lower odds of developing perianal fistula complications (PFCs) in a propensity-matched analysis reported in Gut.
The study included 447 matched patients without baseline perianal fistula; nonpenetrating perianal lesions increased risk of PFCs, while early anti-TNFα strongly reduced that risk—especially in those with perianal lesions. The authors note that timing for initiating early anti-TNFα needs more study.
This report summarizes a published observational study and does not present treatment recommendations. If you or your child has Crohn disease and perianal findings, discuss the potential risks and benefits of early anti-TNF therapy with your gastroenterologist, including available options, monitoring, and insurance/coverage considerations.
Disclosure: one study author reported consulting fees from Janssen; the article is a HealthDay summary of the Gut publication, and full text or abstract may require subscription to view.
This is an observational, propensity-matched study reported in Gut; it supports prior findings but cannot define the exact optimal timing to start anti-TNF therapy. The article is a news summary (HealthDay) of the published study; check the original paper for full methods and limitations before changing care.
